Improved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors

Bural, Gonca G.; Muthukrishnan, Ashok; Oborski, Matthew J.; Mountz, James M.
October 2012
Molecular Imaging & Radionuclide Therapy;Oct2012, Vol. 21 Issue 3, p91
Academic Journal
Objective: To assess the clinical utility of SPECT/ CT in subjects with endocrine and neuroendocrine tumors compared to SPECT alone. Material and Methods: 48 subjects (31 women;17 men; mean age 54�11) with clinical suspicion or diagnosis of endocrine and neuroendocrine tumor had 50 SPECT/CT scans (32 Tc-99m MIBI, 5 post treatment I-131, 8 In-111 Pentetreotide, and 5 I-123 MIBG). SPECT alone findings were compared to SPECT/CT and to pathology or radiological follow up. Results: From the 32 Tc-99m MIBI scans, SPECT accurately localized the lesion in 22 positive subjects while SPECT/CT did in 31 subjects. Parathyroid lesions not seen on SPECT alone were smaller than 10 mm. In five post treatment I-131 scans, SPECT alone neither characterized, nor localized any lesions accurately. SPECT/CT revealed 3 benign etiologies, a metastatic lymph node, and one equivocal lesion. In 8 In-111 Pentetreotide scans, SPECT alone could not localize primary or metastatic lesions in 6 subjects all of which were localized with SPECT/CT. In five I-123 MIBG scans, SPECT alone could not detect a 1.1 cm adrenal lesion or correctly characterize normal physiologic adrenal uptake in consecutive scans of the same patient with prior history of adrenelectomy, all of which were correctly localized and characterized with SPECT/CT. Conclusion: SPECT/CT is superior to SPECT alone in the assessment of endocrine and neuroendocrine tumors. It is better in lesion localization and lesion characterization leading to a decrease in the number of equivocal findings. SPECT/CT should be included in the clinical work up of all patients with diagnosis or suspicion of endocrine and neuroendocrine tumors.


Related Articles

  • Functional imaging in phaeochromocytoma and neuroblastoma with Ga-DOTA-Tyr-octreotide positron emission tomography and I-metaiodobenzylguanidine. Kroiss, Alexander; Putzer, Daniel; Uprimny, Christian; Decristoforo, Clemens; Gabriel, Michael; Santner, Wolfram; Kranewitter, Christof; Warwitz, Boris; Waitz, Dietmar; Kendler, Dorota; Virgolini, Irene Johanna // European Journal of Nuclear Medicine & Molecular Imaging;May2011, Vol. 38 Issue 5, p865 

    Purpose: Ga-DOTA-Tyr-octreotide positron emission tomography (Ga-DOTA-TOC PET) has proven to be superior to In-DTPA-D-Phe-octreotide (In-octreotide) planar scintigraphy and SPECT imaging in neuroendocrine tumours (NETs). Because of these promising results, we compared the accuracy of...

  • Nuclear medicine imaging of neuroendocrine tumours. Al-Nahhas, Adil // Clinical Medicine;Aug2012, Vol. 12 Issue 4, p377 

    The article discusses nuclear medicine imaging of neuroendocrine tumours (NETs), a clinically diverse group of tumours which commonly affect the gastroenteropancreatic tract and lungs. NETs comprise carcinoid tumours and various pancreatic tumours such as gastrinoma, insulinoma, VIPoma,...

  • Quantification of heterogeneity observed in medical images. Brooks, Frank J.; Grigsby, Perry W. // BMC Medical Imaging;2013, Vol. 13 Issue 1, p1 

    Background: There has been much recent interest in the quantification of visually evident heterogeneity within functional grayscale medical images, such as those obtained via magnetic resonance or positron emission tomography. In the case of images of cancerous tumors, variations in grayscale...

  • Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience. Verma, Priyanka; Chanadana; Hephzibah, Julie; Shanthly, Nylla; Oommen, Regi // Indian Journal of Nuclear Medicine;Oct2012, Vol. 27 Issue 4, p246 

    Context: Radiolabelled metaiodobenzylguanidine (MIBG) is commonly used for imaging of neuroendocrine tumors (NETs). The hybrid imaging with single photon emission computerized tomography/computerized tomography (SPECT/CT) co-registration can give that additional edge to this functional imaging...

  • Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to I-MIBG SPECT/CT. Kroiss, Alexander; Shulkin, Barry; Uprimny, Christian; Frech, Andreas; Gasser, Rudolf; Url, Christoph; Gautsch, Kurt; Madleitner, Ruth; Nilica, Bernhard; Sprinzl, Georg; Gastl, Guenther; Fraedrich, Gustav; Virgolini, Irene // European Journal of Nuclear Medicine & Molecular Imaging;Jan2015, Vol. 42 Issue 1, p33 

    Purpose: The aim of this study was to compare the accuracy of I-MIBG SPECT/CT with that of Ga-DOTATOC PET/CT for staging extraadrenal paragangliomas (PGL) using both functional and anatomical images (i.e. combined cross-sectional imaging) as the reference standards. Methods: The study included...

  • Use of 99m-technetium-glucoheptonate as a tracer for brain tumor imaging: An overview of its strengths and pitfalls. Santra, Amburanjan; Kumar, Rakesh; Sharma, Punit // Indian Journal of Nuclear Medicine;Jan-Mar2015, Vol. 30 Issue 1, p1 

    Brain tumors represent a vexing clinical problem in oncology due to their increasing incidence, difficulties in treatment and high rates of recurrence. It is especially challenging to evaluate the posttreatment disease status because differentiation of recurrence from treatment-induced changes...

  • Testing for radioligand sensitivity to endogenous neurotransmitter release. Knudsen, Gitte M. // European Journal of Nuclear Medicine & Molecular Imaging;Mar2009, Vol. 36 Issue 3, p472 

    The author reflects on the mechanism underlying radioligand sensitivity to the release of endogenous neurotransmitters. Results from studies regarding the regulation of the dopaminergic transmitter system in human brain reveal significant findings involving the use of positron emission...

  • I-MIBG scintigraphy/SPECT versus F-FDG PET in paediatric neuroblastoma. Melzer, Henriette Ingrid; Coppenrath, Eva; Schmid, Irene; Albert, Michael H.; von Schweinitz, Dietrich; Tudball, Coral; Bartenstein, Peter; Pfluger, Thomas // European Journal of Nuclear Medicine & Molecular Imaging;Sep2011, Vol. 38 Issue 9, p1648 

    Purpose: To analyse different uptake patterns in I-MIBG scintigraphy/SPECT imaging and F-FDG PET in paediatric neuroblastoma patients. Methods: We compared 23 I-MIBG scintigraphy scans and 23 F-FDG PET scans (mean interval 10 days) in 19 patients with a suspected neuroblastic tumour (16...

  • Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Binnebeek, S.; Vanbilloen, B.; Baete, K.; Terwinghe, C.; Koole, M.; Mottaghy, F.; Clement, P.; Mortelmans, L.; Bogaerts, K.; Haustermans, K.; Nackaerts, K.; Van Cutsem, E.; Verslype, C.; Verbruggen, A.; Deroose, C.; Van Binnebeek, S; Mottaghy, F M; Clement, P M; Deroose, C M // European Radiology;Mar2016, Vol. 26 Issue 3, p900 

    Objectives: To compare the diagnostic accuracy of (111)In-pentetreotide-scintigraphy with (68)Ga-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT)....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics